Please use this identifier to cite or link to this item:
|Title:||MP25-09: The Impact Of United States Preventive Services Task Force (USPTSTF) Recommendation On PSA Testing In Australia.|
|Epworth Authors:||Moon, Daniel|
|Other Authors:||Zargar, Homayoun|
Van den Bergh, Roderick
Van Bruwaene, Siska
|Keywords:||United States Preventive Services Task Force|
Robotic Surgery, Epworth HealthCare, Melbourne, VIC, Australia
Australian Prostate Cancer Research Centre, Epworth Richmond Hospital, Melbourne, Australia.
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
|Citation:||The Journal of Urology; April 2016 vol. 195, Issue 4, Supplement, Pages e281–e282|
|Conference:||The American Urological Association Annual Meeting, 06 May 2016 - 10 May 2016.|
|Conference Location:||San Diego Convention Center, 111 W. Harbor Drive, San Diego, CA 92101.|
|Abstract:||INTRODUCTION AND OBJECTIVES: to assess the impact of 2012 (May) United States Preventive Services Task Force (USPTSTF) recommendation on PSA testing, prostate biopsy and prostatectomy in Australia using Medicare data. METHODS: using Medicare item numbers for PSA (66659), Prostate biopsy (37219), Prostatectomy (37210) and Prostatectomy with lymph node dissection (37211) the occurrences of each procedure was queried per 100 000 capita for consecutive financial years over the period 2000-2015. For each item number reports were also generated for all Australian states. For PSA testing the results were stratified for the three age groups of 45-54, 55-64 and 65-74 years old. RESULTS: steady decline in per capita incidences of all four item numbers assessed were observed for the three consecutive financial years since the publication of USPTSTF recommendation statement. These declines were observed across all states. The nationwide incidences of PSA testing for 2012, 2013, 2014 and 2015 financial years were 485, 478, 457 and 406 per 100 000 capita respectively. Similarly the nationwide incidences of prostate biopsy for 2012, 2013, 2014 and 2015 financial years were 120, 110, 96 and 77 per 100 000 capita respectively. These declines were observed for all the three age groups assessed. CONCLUSIONS: Since the introduction of USPTSTF recommendation statement there has been a steady decline in per capita incidences of PSA testing, prostate biopsy and prostatectomy based on the Australian Medicare data. Whether these declines are in the right direction toward reduction in over diagnosis and over treatment of clinically insignificant prostate cancer or stage migration toward more locally advanced disease due to lost opportunity in diagnosing and treating early clinically significant prostate cancer will remain to be seen.|
|Affiliated Organisations:||Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.|
Department of Urology, University of Leuven, Belgium.
Department of Surgery, University of Melbourne, Victoria, Australia.
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
|Type of Clinical Study or Trial:||Comparative Study|
|Appears in Collections:||Cancer Services|
Epworth Prostate Centre
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.